Cartesian Therapeutics, Inc. RNAC
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
Revenue compounded at −30.0% a year over the five years to FY2025.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Return on equity has no reading this year — return on capital employed, just below, still does: -41%.
The 12-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.1 | −0.0 | −0.1 | 0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.1 | −0.0 | −0.1 | 0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Income tax $B | −0.0 | 0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | ◌ | ◌ | ◌ | ◌ | ◌ |
| Net income $B | −0.1 | −0.1 | −0.2 | 0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.1 | −0.0 | −0.1 | −0.0 | −0.1 | 0.0 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −5.02 | −4.49 | −49.76 | 0.10 | −0.22 | −0.68 | −1.22 | −2.92 | −3.20 | −3.89 | −15.13 | −7.84 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE % | — | — | — | 60.8 | — | — | — | — | −122.4 | — | — | — |
| Shares out B | 0.03 | 0.03 | 0.16 | 0.15 | 0.12 | 0.11 | 0.09 | 0.02 | ◌ | 0.02 | 0.00 | ◌ |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 12 of the 12 fiscal years we could check. 16 checks were skipped: the balance sheet is not tagged before 2015. Seven checks were skipped: EPS is not tagged before 2014.